Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

519
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
519
Cancer Vaccines01:30

Cancer Vaccines

569
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
569
Cross-reactivity00:42

Cross-reactivity

31.8K
Overview
31.8K
Vaccinations01:51

Vaccinations

46.6K
Overview
46.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent sheaf Laplacian analysis of protein stability and solubility changes upon mutation.

Protein science : a publication of the Protein Society·2026
Same author

Correlated clustering and projection for dimensionality reduction.

Machine learning: science and technology·2026
Same author

VARIANT: Web Server for Decoding and Analyzing Viral Mutations at Genome and Protein Levels.

ArXiv·2026
Same author

Manifold topological deep learning for biomedical data.

Nature communications·2026
Same author

A review of recent advances in generative artificial intelligence models for biomolecular sciences.

Acta pharmaceutica Sinica. B·2026
Same author

CAP: Commutative algebra prediction of protein-nucleic acid binding affinities.

Machine learning: science and technology·2026

Related Experiment Video

Updated: Oct 20, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Emerging vaccine-breakthrough SARS-CoV-2 variants.

Rui Wang1, Jiahui Chen1, Yuta Hozumi1

  • 1Department of Mathematics, Michigan State University, MI 48824, USA.

Arxiv
|September 14, 2021
PubMed
Summary

New SARS-CoV-2 variants evolve through spike protein mutations, driving increased infectivity and vaccine escape. Understanding these co-mutations is crucial for developing next-generation vaccines against emerging variants.

More Related Videos

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.4K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K

Related Experiment Videos

Last Updated: Oct 20, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K
Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
06:08

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

1.4K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K

Area of Science:

  • Virology and Molecular Biology
  • Genomics and Bioinformatics
  • Immunology

Background:

  • The global surge in COVID-19 is driven by new SARS-CoV-2 variants with numerous spike protein mutations, complicating vaccine efficacy.
  • Understanding the molecular mechanisms of viral transmission and evolution is essential for predicting future variants and designing broadly protective vaccines and therapeutics.

Approach:

  • Integrated analysis of genomic data from over 1.4 million SARS-CoV-2 isolates, antibody data, and mutation information.
  • Employed topological data analysis and deep learning to model SARS-CoV-2 evolution and forecast vaccine-escape variants.
  • Quantitatively analyzed co-mutations on the spike protein Receptor Binding Domain (RBD) to explain infectivity and virulence.

Key Points:

  • Infectivity-enhancing and antibody-disruptive co-mutations on the spike protein RBD explain the behavior of current SARS-CoV-2 variants.
  • The Lambda variant exhibits infectivity comparable to Delta but with increased vaccine resistance.
  • Analysis identified emerging vaccine-breakthrough co-mutations in 20 countries, highlighting global trends.

Conclusions:

  • Natural selection drives viral evolution in unvaccinated populations, while antibody-evading co-mutations will fuel variant growth in vaccinated populations.
  • Identified specific co-mutations with high likelihood of dominance and potential to evade existing vaccines.
  • Urgent development of new vaccines targeting these predicted dominant co-mutations is necessary.